| Stage | NVST | % of rev | XRAY | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $731M | 100.00% | $898M | 100.00% | XRAY ×1.23 |
| Gross profit | $407M | 55.72% | $493M | 54.90% | NVST +0.8pp |
| Operating income | $80M | 10.99% | $82M | 9.13% | NVST +1.9pp |
| Pre-tax income | $74M | 10.18% | $72M | 8.02% | NVST +2.2pp |
| Net income | $54M | 7.35% | $36M | 4.01% | NVST +3.3pp |
| Stage | NVST | XRAY | Gap · A − B |
|---|---|---|---|
| Revenue | $731M100.00% | $898M100.00% | XRAY ×1.23 |
| Gross profit | 55.72%$407M | 54.90%$493M | NVST +0.8pp |
| Operating income | 10.99%$80M | 9.13%$82M | NVST +1.9pp |
| Pre-tax income | 10.18%$74M | 8.02%$72M | NVST +2.2pp |
| Net income |
| 7.35%$54M |
| 4.01%$36M |
| NVST +3.3pp |
None
NVST 10-KFeb 13 '25
“Historically, a substantial portion of our sales had come from a limited number of distributors, particularly Henry Schein, which accounted for approximately 10% of our sales in 2024 and 2023.”
XRAY 10-KFeb 27 '25
“Together, our two largest distributors, Patterson Companies, Inc. ("Patterson") and Henry Schein, Inc. ("Henry Schein"), accounted for approximately 13% of our annual revenue for the year ended December 31, 2024.”